{"DataElement":{"publicId":"3257655","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination Ind-2","preferredDefinition":"the yes/no indicator related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"3257654v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3257654","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"2543047v1.0:3257652v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3257652","version":"1","preferredName":"Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination","preferredDefinition":"A quantitative measurement of alkaline phosphatase present in a sample.:Activity measured as a test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferases (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. (NCI):Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C64432:C25202:C25293:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkaline Phosphatase Measurement","conceptCode":"C64432","definition":"A quantitative measurement of alkaline phosphatase present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Aspartate Aminotransferase","conceptCode":"C25202","definition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alanine Aminotransferase","conceptCode":"C25293","definition":"A family of pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Alanine aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-alanine to alpha-ketoglutarate forming pyruvate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FD5CDF-1741-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"ONEDATA","dateModified":"2011-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FD5CDF-1752-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000287","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104909","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"10000288","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"10000081","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4104906","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000082","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4104996","version":"1","longName":"GOG-0279","context":"NRG"},{"publicId":"4104900","version":"1","longName":"GOG-0277","context":"NRG"}]}],"AlternateNames":[{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"LAB_PROC_ALK_PHOS_ED","type":"Context Short Name","context":"NRG"},{"name":"GOG","type":"USED_BY","context":"NRG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"3257654v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Are the AST(SGOT) and ALT(SGP","type":"Preferred Question Text","description":"Are the AST(SGOT) and ALT(SGPT) and alkaline phosphatase less than or equal to 2.5 times the institutional upper limit of normal","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Are the SGOT (AST), SGPT (ALT) and Alkaline Phosphatase less than or equal to 2.5 x ULN?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Are the AST, ALT, and Alkaline Phosphatase less than or equal to 3 x ULN?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Are pre-study AST (SGOT) / ALT (SGPT) <= 2.0 x upper limit of normal within 7 days prior to first dose of study drug?","url":null,"context":"CTEP"},{"name":"GOG_CRF Text","type":"Alternate Question Text","description":"Are the SGOT/AST and Alkaline Phosphatase less than or equal to 2.5 times the upper limit of normal in the absence of liver metastasis OR are the SGOT/AST and Alkaline Phosphatase less than 5.0 times the ULN in the presence of liver metastasis?","url":null,"context":"NRG"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Are the SGOT (AST), SGPT (ALT) and Alkaline Phosphatase less than or equal to 2.5 x ULN within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 1","type":"Alternate Question Text","description":"AST(SGOT) and ALT (SGPT) <= 5.0 x institutional upper limit of normal (ULN) within 14 days prior to registration on study?","url":null,"context":"NRG"},{"name":"Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal if liver involvement?","type":"Alternate Question Text","description":"Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal if liver involvement?","url":null,"context":"Theradex"},{"name":"NRG_CRF Text2","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 2.5 x ULN?","url":null,"context":"NRG"},{"name":"NRG_CRF text 3","type":"Alternate Question Text","description":"Are the AST/ALT less than or equal to 2.5 the institutional ULN?","url":null,"context":"NRG"},{"name":"NRG_CRF text 4","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 3 x ULN?","url":null,"context":"NRG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Does patient have serum AST and/or ALT > 3 X upper limit of institutional normal?","url":null,"context":"COG"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Are AST(SGOT) and ALT(SGPT) <6 x institutional ULN","url":null,"context":"NRG"},{"name":"CRF_Text_5","type":"Alternate Question Text","description":"Does the patient have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 x ULN within 14 days prior to registration?","url":null,"context":"CTEP"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Is the patient's AST/ALT less than or equal to 3 times the institutional upper limit of normal (ULN)","url":null,"context":"CTEP"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Is the patient's SGPT (ALT) less than or equal to 3 times the upper limits of normal?","url":null,"context":"CTEP"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Is the patient's AST and ALT <= 3 x ULN for the lab?","url":null,"context":"CTEP"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Is AST and ALT <= 2.5 x ULN?","url":null,"context":"CTEP"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"Is AST and ALT <= 3 x ULN?","url":null,"context":"CTEP"},{"name":"CRF Text 12","type":"Alternate Question Text","description":"Is aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) <= 3 x ULN?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Are the AST(SGOT)/ALT(SGPT) less than or equal to 3 times the upper limit OR are the AST(SGOT)/ALT(SGPT) less than or equal to 5.0 times the ULN with liver involvement?","url":null,"context":"NRG"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Is the patient's AST and ALT less than or equal to 2.5 x ULN for the lab or less than or equal to 5 x ULN for patients with liver metastases within 14 days prior to randomization?","url":null,"context":"CTEP"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Does patient have ALT and AST less than or equal to 3 x ULN within 14 days prior to registration?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Has patient had ALT and AST less than or equal to 3 x ULN within 14 days prior to enrollment?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Is aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) less than or equal to 2.5 x ULN?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Is the patient's AST and ALT less than or equal to 2.5 x ULN for the lab or less than or equal to 5 x ULN for patients with liver metastases, within 14 days prior to study entry?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Are AST and ALT less than 2.5 x ULN for the lab within 28 days before study entry?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_7","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 3 x ULN within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_6","type":"Alternate Question Text","description":"Are AST(SGOT) and ALT(SGPT) less than or equal to 3 x ULN within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_5","type":"Alternate Question Text","description":"Are AST and ALT less than 2.5 x ULN for the lab within 28 days before randomization?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_8","type":"Alternate Question Text","description":"Is aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) less than or equal to 3 x ULN?","url":null,"context":"NRG"},{"name":"Alliance text 1","type":"Alternate Question Text","description":"Is AST or ALT > 3 x ULN clearly attributable to liver metastases?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_9","type":"Alternate Question Text","description":"Are AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Are AST (SGOT) and ALT (SGPT) less than or equal to 3 x institutional ULN within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 5.0 x ULN within 14 days prior to registration?","url":null,"context":"NRG"},{"name":"NRG CRF Text 3","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 5.0 x ULN within 14 days prior to second registration?","url":null,"context":"NRG"},{"name":"NRG CRF Text 4","type":"Alternate Question Text","description":"Are the patient's AST and ALT less than or equal to 3 x ULN for the lab?","url":null,"context":"NRG"},{"name":"NRG CRF Text 5","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 3 x institutional upper limit of normal (ULN)?","url":null,"context":"NRG"},{"name":"NRG CRF Text 6","type":"Alternate Question Text","description":"Are AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional ULN within 16 weeks prior to pre-entry?","url":null,"context":"NRG"},{"name":"NRG CRF Text 7","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 1.5 x institutional upper limit of normal (ULN)?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_10","type":"Alternate Question Text","description":"Is the patient's AST and ALT less than or equal to 2.5 x ULN for the lab or less than or equal to 5 x ULN for patients with liver metastases, within 14 days prior to Step 1/Study entry?","url":null,"context":"NRG"},{"name":"NRG_CRF text 8","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 5x ULN?","url":null,"context":"NRG"},{"name":"NRG_CRF text 9","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 5.0 x ULN","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_11","type":"Alternate Question Text","description":"Are AST and ALT less than 2.5 x ULN for the lab within 28 days before Step 1/Study entry?","url":null,"context":"NRG"},{"name":"NRG_CRF text 13","type":"Alternate Question Text","description":"Are AST and ALT less than or equal to 3 x institutional ULN?","url":null,"context":"NRG"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A8FD5CDF-1764-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"TYRRELLM","dateModified":"2023-10-25","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"10.25.2023 Added AQT per requested ticket CADSR0002989_mmt\r\n10.2.2023 Added AQT per request CADSR0002902 _mmt\r\n9.29.2023 Added AQT per request CADSR0002901_mmt\r\n9.28.2023 Added AQT per request CADSR0002895_mmt\r\nAdded AQT for NRG 5/24/22 CJL 2022.11.15 AQT added for ticket request CADSR0001687. ak","unresolvedIssues":null,"deletedIndicator":"No"}}